About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Maryland | 17,687 Studies Near You | Clareo Health

Clinical Trials LocationsMaryland

Clinical Trials in Maryland

Discover 17,687 clinical trials near Maryland. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9341-9360 of 17,687 trials

COMPLETEDPhase 49.2 miles

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350

This research study involves testing of a device that can give injections (shots) without the use of a needle.

University of Maryland, Baltimore60 participantsStarted Jan 2010

College Park, Maryland, United States

TERMINATEDPhase 312 miles

Extension Study Of Tanezumab In Osteoarthritis

NCT00809783

Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab

Pfizer2,147 participantsStarted Feb 2009

Anniston, Alabama, United States • Anniston, Alabama, United States • Anniston, Alabama, United States +223 more locations

Find Trials by Condition in Maryland

Breast Cancerin Maryland Lung Cancerin Maryland Prostate Cancerin Maryland Colorectal Cancerin Maryland Melanomain Maryland Leukemiain Maryland Lymphomain Maryland Pancreatic Cancerin Maryland Ovarian Cancerin Maryland Brain Cancerin Maryland Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 313 miles

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496

This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bevacizumab together with intravenous chemotherapy is more effective than giving bevacizumab together with intraperitoneal chemotherapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+35 more

National Cancer Institute (NCI)1,560 participantsStarted Aug 2009

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +500 more locations

COMPLETED15 miles

Familial Schizophrenia and Spectrum Personality Disorders

NCT00666146

We propose to recruit 150 case families (i.e., families with a schizophrenia proband), 150 control families, and 45 control subjects who exhibit schizophrenia spectrum personality symptoms in the absence of a family history of schizophrenia. Participants will undergo a number of clinical, electrophysiological, perceptual, and cognitive assessments. These data will be used to identify phenotypes likely to be associated with genetic risk for schizophrenia, and to determine how these phenotypes aggregate in families. Some of the analyses will focus on examining associations between candidate genes and these alternative phenotypes. Thus if we are not able to recruit relatives we may still collect these phenotypic data in probands and their genetic sample for future genotype/phenotype association studies. Testing procedures require a 10-12 hour time commitment and testing will be completed over 2 or more days. Participants will be asked to give a blood (or saliva if difficult to obtain blood sample for instance because of fear of blood draws), which will be stored for future genetic analyses.

University of Maryland, Baltimore539 participantsStarted Jul 2004

Baltimore, Maryland, United States • Baltimore, Maryland, United States • Catonsville, Maryland, United States

TERMINATEDPhase 117 miles

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

NCT03478904

Background: Enzalutamide is given to treat metastatic prostate cancer. But it takes 4 pills to deliver the effective dose. This can be difficult for people already taking multiple drugs. And swallowing may be difficult for some people. Researchers want to test out a new way of giving enzalutamide by mouth. They want to see if giving a person the liquid taken from inside the standard 4 gelatin capsules is handled by the body in the same way as giving them the capsules whole. Objectives: To compare how capsule and liquid forms of enzalutamide are handled by people with prostate cancer. Eligibility: Men at least 18 years old with prostate cancer Design: Participants will be screened with a heart test (electrocardiogram), medical history, and physical exam. A tissue sample or lab reports will be reviewed. During the study, participants will repeat screening tests and have urine tests. Participants will be randomly assigned to get the study drug in one of two orders: either the as capsules then the liquid form (Arm A) or as the liquid form then the capsule form (Arm B). Participants will be counseled about birth control. The study will have 2 periods with a minimum 42 day break in between. On Day 1 of Period 1 and Day 1 of Period 2, participants will be admitted to the hospital. They will get one dose of the study drug. They cannot eat or drink anything except water for at least 10 hours before and for 4 hours after the study drug. Their blood will be sampled over 24 hours. Lunch and dinner will be served. Participants will answer questions after taking the liquid form. Participants will have blood drawn on Day 3, Day 8, and Day 42.

Prostate Cancer

National Cancer Institute (NCI)1 participantsStarted Mar 2020

Bethesda, Maryland, United States

UNKNOWNPhase 217 miles

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

NCT04874506

MBM-02 (Tempol) is an HIF-1 and HIF-2 inhibitor that is being tested as an addition to standard of care treatment that includes radiotherapy and TMZ. MBM-02's ability to increase progression free survival and decrease side effects of TMZ and radiotherapy treatment will be assessed.

GlioblastomaGlioblastoma Multiforme

Matrix Biomed, Inc.55 participantsStarted Jun 2021

Washington D.C., District of Columbia, United States

COMPLETEDPhase 319 miles

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

NCT01027949

This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise capacity after 1 year of treatment.

Pulmonary Arterial Hypertension

United Therapeutics894 participantsStarted Jan 2007

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +131 more locations

COMPLETEDNA19 miles

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

NCT02700464

Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of bladder cancer.

Nucleix Ltd.680 participantsStarted Sep 2016

Denver, Colorado, United States • Baltimore, Maryland, United States • Troy, Michigan, United States +8 more locations

COMPLETED19 miles

Brain Circuits in Schizophrenia and Smoking

NCT01425684

The principle aim of the project is to identify the key brain circuits associated with smoking and especially smoking in high risk population. The investigators hope that the study will provide concrete biomarkers for new therapeutic development and ultimately reducing the smoking related health burden.

SchizophreniaSchizoaffective DisorderSchizophreniform Disorder

University of Maryland, Baltimore837 participantsStarted Dec 2010

Baltimore, Maryland, United States

WITHDRAWNPhase 131 miles

PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

NCT03706274

The purpose of this first-in-human study of CX-188 is to characterize the safety, tolerability, pharmacokinetics (PK), and antitumor activity of CX-188 in adult subjects with metastatic or advanced unresectable solid tumors that progressed on standard therapy: PROCLAIM: PRObody Clinical Assessment in Man CX-188 clinical trial 001

Solid Tumor, Adult

CytomX TherapeuticsStarted Jan 2020

Fairfax, Virginia, United States

TERMINATEDPhase 296 miles

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

NCT01098240

The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) using the Montgomery Asberg Depression Rating Scale (MADRS). 2) Evaluate the safety and tolerability of CP 601,927 in patients with MDD on ADT.

Major Depressive Disorder

Pfizer297 participantsStarted Jun 2010

Little Rock, Arkansas, United States • Beverly Hills, California, United States • Garden Grove, California, United States +55 more locations

COMPLETEDNA107 miles

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1)

NCT03107949

An early feasibility study to investigate the safety and feasibility of the Lungpacer Diaphragm Pacing Therapy System (DPTS) as a therapy to recondition and strengthen the diaphragm of patients who have been intubated and invasively mechanically ventilated for \> or = 7 days, have failed two or more spontaneous breathing trials (SBT), and were not hypervolemic during the latest SBT.

Ventilator Induced Diaphragm Dysfunction

Lungpacer Medical Inc.9 participantsStarted Jun 2017

Gainesville, Florida, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States +1 more locations

COMPLETEDPhase 3110 miles

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

NCT01473524

The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with primary biliary cirrhosis (PBC).

Primary Biliary Cirrhosis

Intercept Pharmaceuticals217 participantsStarted Jan 2012

Sacramento, California, United States • San Diego, California, United States • Aurora, Colorado, United States +56 more locations

TERMINATEDPhase 2120 miles

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT03844932

Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).

Colitis, Ulcerative

Sublimity Therapeutics Holdco Limited235 participantsStarted Jan 2019

Palm Springs, California, United States • Largo, Florida, United States • New Port Richey, Florida, United States +86 more locations

COMPLETEDPhase 2127 miles

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

NCT02966834

This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will receive either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram \[mg\], 90 mg or 180 mg taken once daily or 90 mg twice daily). Participants on GSK2330672 will also receive placebo tablets to maintain blinding. The study has a prospectively defined adaptive design that will utilize interim data to further inform and potentially optimize the doses under investigation. Hence, additional dose regimen may be added during study. The total duration of a participant in the study will be up to 45 days of screening and 24 weeks of study including follow-up.

GlaxoSmithKline147 participantsStarted Jan 2017

Phoenix, Arizona, United States • Sacramento, California, United States • Miami, Florida, United States +63 more locations

WITHDRAWNPhase 2187 miles

A Study of JNJ-64304500 in Participants With Alopecia Areata

NCT04740970

The purpose of this study is to evaluate the clinical response of 22 weeks of study intervention with JNJ-64304500, compared with placebo, in participants with moderate to severe alopecia areata (AA).

Alopecia Areata

Janssen Research & Development, LLCStarted Mar 2021

Tampa, Florida, United States • Plainfield, Indiana, United States • Louisville, Kentucky, United States +19 more locations

COMPLETEDPhase 1/2187 miles

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

NCT03466320

This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r/r AML/MDS patients.

Celyad Oncology SA21 participantsStarted Sep 2018

Aurora, Colorado, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +4 more locations

COMPLETEDPhase 2187 miles

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

NCT01835626

Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and tolerable. The purpose of this study is to assess the safety and tolerability of combined radiation therapy and vismodegib. This combination may increase the chances of the tumors being destroyed or unable to spread to other parts of the body in people with locally advanced basal cell carcinoma of the head and neck.

Locally Advanced Basal Cell CarcinomaSkin CancerCutaneous Malignancy

Sue Yom24 participantsStarted May 2013

San Francisco, California, United States • New York, New York, United States

COMPLETEDPhase 3348 miles

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

NCT03216226

The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon\* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. \*dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207

HypoglycemiaDiabetes Mellitus, Type 1

Zealand Pharma112 participantsStarted Jun 2017

Orlando, Florida, United States • Meridian, Idaho, United States • Graz, Austria +4 more locations

RECRUITING2306 miles

Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

NCT03961776

feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.

Rectal Adenocarcinoma

Institut Paoli-Calmettes39 participantsStarted Jun 2020

Los Angeles, California, United States • Marseille, Bouches Du Rhone, France

PreviousPage 468 of 885Next

in Maryland

Heart Diseasein Maryland